Presentations include updated data from Phase 1 study of SQ3370 in patients with advanced solid tumors and nonclinical data on SQ3370 combined with cancer immunotherapies

SAN FRANCISCO, Nov. 4, 2021 – Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) platform, today announced upcoming presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, taking place virtually and in person in Washington, DC, on November 10–14, 2021, and at the Connective Tissue Oncology Society’s (CTOS) Annual Meeting, being held virtually on November 10–13, 2021. Shasqi will present updated data from its Phase 1 clinical study of SQ3370 in patients with advanced solid tumors, and nonclinical data on SQ3370 in combination with cancer immunotherapies.

“We look forward to these upcoming presentations where we will share the progress of our Phase 1 study, present data on the compatibility of SQ3370 treatment with a local immune response and increases in certain circulating immune cells, and review nonclinical evidence that our click-chemistry approach has additional potential when combined with other cancer therapies,” said José M. Mejía Oneto, M.D., Ph.D., Founder and CEO of Shasqi.

SITC 36th Annual Meeting

The clinical data will be presented at the following poster session:

• Title: Pharmacokinetic and immunologic data from a Phase I study of the click chemistry-based therapy SQ3370 in advanced solid tumors and soft-tissue sarcoma provides proof-of-concept for the CAPAC platform
• Presentation number: 367
• Date and time: Friday, Nov. 12, 2021, 7 AM – 8:30 PM EST
• Presenter: Vivek A. Bhadri, M.D., Ph.D., Medical Oncologist at Chris O’Brien Lifehouse in Australia

The pre-clinical data will be presented at the following poster session:

• Title: Combination of click chemistry-based SQ3370 with immunotherapies enhances antitumor effect in murine tumors with minimized systemic toxicity
• Presentation number: 695
• Date and time: Friday, Nov. 12, 2021, 7 AM – 8:30 PM EST
• Presenter: Amir Mahmoodi, Scientist at Shasqi

CTOS Annual Meeting

The clinical data will be presented at the following poster session:

• Title: First-in-human trial of SQ3370 in relapsed or refractory soft tissue sarcoma and other solid tumors: proof-of-concept for the click chemistry-based CAPAC platform
• Presentation number: P182
• Date and time: Friday, Nov. 12, 2021, 2:30 – 3:15 PM EST
• Presenter: Alexander Guminski, M.D., Ph.D., Medical Oncologist at Royal North Shore Hospital in Australia

The pre-clinical data will be presented at the following poster session:

• Title: Click Activated Protodrugs Against Cancer (CAPAC) Platform Enhances Antitumor Efficacy, Safety and Pharmacokinetics of Cancer Therapeutics
• Presentation number: P019
• Date and time: Thursday, Nov. 11, 2021, 2:30 – 3:15 PM EST
• Presenter: Sangeetha Srinivasan, Ph.D., Associate Director at Shasqi

‍